Disclosures for "Effectiveness of Cenobamate in Reducing Focal Onset Seizure-related Hospitalizations: A Retrospective Claims-based Analysis"
-
Dr. Urban has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neuropace.
-
Mr. Stern has received personal compensation for serving as an employee of SK Life Science.
-
Mr. Wade has nothing to disclose.
-
Dr. Schabert has nothing to disclose.